Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche buys BioVeris to expand immunochemistry biz

This article was originally published in The Gray Sheet

Executive Summary

Roche gains expanded access to electrochemiluminescence (ECL) technology used in its Elecsys automated immunodiagnostic systems through the $600 million purchase of its technology licensor BioVeris, announced April 4. The deal allows Roche Diagnostics to expand its immunochemistry business from the human diagnostics field into new market segments such as life science research and development, patient self testing, and drug discovery and development, among other opportunities, the firm says. Roche is paying $21.50 per share for BioVeris - a 58% premium over its April 3 closing price of $13.60. BioVeris reported revenue of $9.1 million for its fiscal third quarter (ended Dec. 31), up 65% from the year-ago quarter largely due to a $2.8 million payment from Roche to account for certain sales by Roche in 2004 that went beyond the scope of the firms' license deal. "This acquisition ensures that Roche will be able to provide unrestricted [ECL] access to all customers," Roche says...

You may also be interested in...



Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel